Phesi

79d18b_23cffd755ae14586a71822aae7b8fb83~mv2

Patient Recruitment for Melanoma Immunotherapy Trial

Situation An innovative biotech company that specializes in developing DNA-based intratumoral immunotherapies needed help in recruiting patients unresponsive to anti-PD-1 therapy into a stage III/IV melanoma trial. Analysis Phesi worked with the CEO and Chief Clinical and Regulatory Officer over a 4-week period to conduct a competitive analysis, reviewing enrollment rates in top recruiting centers across 39 recent, relevant trials: Phesi…

imf

Integrated Clinical Development Planning for Iron Overload Candidate

Situation An exciting biotechnology company that develops gene therapeutic technology based on RNA wanted to develop a baseline, integrated development plan for a lead iron overload (IO) candidate.  The client was keen to take a data led approach to understand and document the following: Competitor activity, dosing and development status, including relevant input for strategic business development activities and interactions…

case-2

Cardiovascular Study Protocol Feasibility

Situation Phesi’s client was designing and planning a Phase II study for a unique cardiovascular (CV) indication. Its compound was first in class, and the first to target a particular CV dysfunction. The client requested insights from similar historical studies to consider what may impact trial operational performance. Analysis Phesi selected 37 trials from its comprehensive clinical trial database, with…

img

Troubleshooting an Under-Performing GI Trial

Situation A global pharmaceutical company was experiencing significant recruitment challenges in a priority Phase III gastroenterology trial, as competitors were running concurrent studies in the same patient population. Site activation was significantly below expectations for this type of trial, and the CRO was proposing to add further sites – despite resources spread thin and with budgets under pressure. The company brought…

Gen Li Interviewed By Cornell Enterprise

(CORNELL ENTERPRISE) February 19 2019 Journalist Dick Anderson conducted an interview with Dr. Gen Li, founder and president of Phesi. “Gen Li was an instructor of neuroscience at Weill Cornell Medicine in 1996 when he enrolled in the inaugural class of Johnson’s One-Year MBA program for students with advanced technology degrees. He recalls a team-building session when a peer said, “Gen, you have…

Phesi At The 8th CROWN Congress

(CROWN CONGRESS) January 22 2019 Phesi is a proud sponsor and presenter at the 8th CROWN congress in Orlando, Florida. The CMO of Phesi, Dr. Paul Chew gives a talk titled “Smarter Trials = Faster Cures: 3 Things You Need to Get Right”. The presentation slides can be downloaded here. About the 8th CROWN congress This year’s CROWN Congress will…

Phesi Selected As Finalist For 2018 Scrip Award

(BUSINESS WIRE) October 10, 2018 EAST LYME, Conn.  Phesi, a technology-enabled, data-driven provider of premier clinical development services, today announced it is a finalist for a 2018 Scrip Award, one of the pharmaceutical and biotech industries’ most prestigious honors. The company has been selected as one of six finalists in the Best Technological Development in Clinical Trials – Tech Sponsor-focused…